Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

Amgen stock last at USD 410.86, up 1.19 percent in New York trading

Market commentary AI-generated analysis

📈 Amgen stock closed at USD 410.86, up 1.19 percent or USD 4.82 from the prior session's close of USD 406.04.

📊 The share price opened at USD 408.25 and reached an intraday high of USD 411.00 before settling.

📉 Trading volume was recorded at 684,284 shares as of 1:17:34 p.m. ET on September 25, 2026.

🏆 Amgen's gain exceeded the S&P 500's 0.53 percent advance by 0.66 percentage points.

💰 The stock traded USD 36.17 below its 52-week high of USD 447.03 and USD 141.09 above its low.

🌍 Market gains were driven by declining oil prices, with the 10-year Treasury yield at 5.225 percent.

🔬 Amgen's performance trailed healthcare competitor Moderna, which rose 1.46 percent during the same session.

📝 Analyst consensus recommendation is Hold with a price target of USD 389.22 based on September 25 data.

Bullish Signals
  • Amgen stock gained 1.19 percent, outperforming the S&P 500's 0.53 percent rise during the trading session.
  • The company's shares traded USD 141.09 above its 52-week low of USD 269.77, indicating sustained support levels.
Risk Factors
  • Amgen's share price remained USD 36.17 below its 52-week high of USD 447.03, suggesting room for further upside.
  • The stock underperformed healthcare peer Moderna, which rose 1.46 percent while Amgen gained only 1.19 percent.
Full Analysis
Amgen Inc. shares closed at USD 410.86 on September 25, 2026, representing a gain of 1.19 percent or USD 4.82 from the previous session's close of USD 406.04. The stock opened at USD 408.25 and traded within an intraday range of USD 6.81, reaching a high of USD 411.00 before settling slightly below that peak. The performance of Amgen's stock outpaced the broader market indices during the session, rising significantly more than the S&P 500's 0.53 percent advance. At the time of the report at 1:17:34 p.m. ET, trading volume stood at 684,284 shares, with the share price remaining well below its 52-week high of USD 447.03. Market conditions on September 25 were influenced by declining oil prices and elevated long-term yields, with the 10-year Treasury yield at 5.225 percent. While Amgen's gain was solid, it trailed healthcare peer Moderna, which rose 1.46 percent, as broader market uncertainty persisted regarding geopolitical risks and monetary policy. Analyst consensus for Amgen remained a Hold recommendation with a target price of USD 389.22 according to data from September 25. The stock maintained a substantial buffer above its 52-week low of USD 269.77, indicating continued investor interest despite the gap below recent highs.